Curium completes acquisition of Abscint SA for HER2-targeted PET imaging asset

Curium has acquired Belgium-based clinical-stage radiopharmaceutical company Abscint SA. The deal gives Curium global rights to develop, manufacture, and commercialize ABS-011, a gallium-68-labeled PET imaging agent designed to detect HER2 expression in breast and gastric cancers. ABS-011 uses a radiolabeled single-domain antibody engineered for rapid HER2 binding with quick blood clearance, enabling same-day whole-body imaging. The asset is currently in Phase IIb evaluation in the HERMIA trial in Belgium, and Curium plans to support its advancement toward regulatory submission.